We thus speculate that BM-MSCs may improve lung morphofunction for several reasons: (1) intravenously administered BM-MSCs accumulate mainly in lung tissue [46]—more beneficial effects would thus occur in the lung than in other organs; (2) the decrease in tissue parasitemia would be associated with increased numbers of lung tissue phagocytic cells [47]; and (3) VEGF, which is the main factor implicated in malaria-induced lung injury [45], would be reduced. Here, VEGFA is linked to parasitic infectious disease.